Lixte Biotechnology Faces Delisting Concerns
Ticker: LIXT · Form: 8-K · Filed: Feb 21, 2025 · CIK: 1335105
Sentiment: bearish
Topics: delisting, listing-standards, regulatory-filing
TL;DR
Lixte Biotech might get delisted - big trouble for shareholders.
AI Summary
Lixte Biotechnology Holdings, Inc. filed an 8-K on February 21, 2025, reporting a notice of delisting or failure to meet continued listing standards as of February 19, 2025. The company, incorporated in Delaware, is based in Pasadena, California, and its principal executive offices are located at 680 East Colorado Boulevard, Suite 180.
Why It Matters
This filing indicates potential issues with Lixte Biotechnology's ability to remain listed on an exchange, which could significantly impact its stock liquidity and investor confidence.
Risk Assessment
Risk Level: high — A notice of delisting or failure to meet listing standards poses a significant risk to the company's continued operation and stock value.
Key Players & Entities
- LIXTE BIOTECHNOLOGY HOLDINGS, INC. (company) — Filer of the 8-K report
- February 19, 2025 (date) — Date of the earliest event reported
- February 21, 2025 (date) — Date the 8-K was filed
- 680 East Colorado Boulevard , Suite 180 Pasadena , California 91101 (location) — Principal executive offices address
FAQ
What specific listing rule or standard has Lixte Biotechnology Holdings, Inc. failed to meet?
The filing does not specify the exact rule or standard that was not met, only that a notice of delisting or failure to satisfy a continued listing rule or standard has been issued.
What is the immediate impact of this notice on Lixte Biotechnology's stock trading?
The filing indicates a potential delisting, which could lead to the stock being transferred to a different exchange or OTC market, or potentially being delisted entirely, affecting its trading status.
When was the event that triggered this 8-K filing?
The earliest event reported in this filing occurred on February 19, 2025.
What is the company's primary business as indicated by its SIC code?
The company's Standard Industrial Classification (SIC) code is 2834, which corresponds to Pharmaceutical Preparations.
Has Lixte Biotechnology Holdings, Inc. previously changed its name?
Yes, the company was formerly known as SRKP 7 INC, with a name change date of August 3, 2005.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on February 21, 2025 regarding LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT).